03.03.25 -- STREAM Edition: Mastering CDMO Collaboration And Optimizing Biologic Manufacturing For 2025

Our panelists have some intriguing thoughts about how to negotiate the purchase of new equipment needed for your program at your CDMO.

Review the efficacy of fast stable pools in generating purified product at an early stage, and learn how to accelerate the journey toward first-in-human trials and proof-of-concept studies.

Gain greater confidence in your container closure system selection by utilizing a stepwise and data-driven approach to predicting and verifying container closure integrity.

Partnering with a provider that prioritizes quality, yield optimization, and efficiency not only ensures product safety but also helps reduce operational costs and improve overall production outcomes.

In this session, Chief Scientific Officer Dr. Andy Lewis delves into the key drivers shaping peptide drug development and explores innovative delivery options to enhance therapeutic outcomes.

Review a case study describing the selection of the optimal solid form of an API, specifically designed for pulmonary administration through the pulmonary route, and its impact.

This technology utilizes a cell-free, enzymatic DNA manufacturing process that accelerates linDNA template production, allowing you to expedite your mRNA research and development pipeline.

Regulated industries face rising demand, tech breakthroughs, and regulatory harmonization. Discover how contract manufacturers must leverage AI and cloud solutions to stay agile and compliant in the future.

Explore the process of constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment, designed to efficiently scale RNA-LNP therapies for broader applications.

Hear an industry expert share his perspective from both the pharmaceutical and CDMO sides on why partnering with a collaborative CDMO can make a significant impact on success.